Anti-oxidative and Anti-cancer Activities of Ethanol Extract of Litsea populifolia |
Jin, Soojung
(Blue-Bio Industry Regional Innovation Center, Dong-eui University)
Oh, You Na (Blue-Bio Industry Regional Innovation Center, Dong-eui University) Jeong, Hyun Young (Blue-Bio Industry Regional Innovation Center, Dong-eui University) Yun, Hee Jung (Division of Applied Bioengineering, College of Engineering, Dong-eui University) Park, Jung-ha (Division of Applied Bioengineering, College of Engineering, Dong-eui University) Kwon, Hyun Ju (Blue-Bio Industry Regional Innovation Center, Dong-eui University) Kim, Byung Woo (Blue-Bio Industry Regional Innovation Center, Dong-eui University) |
1 | Wu, W., Fan, Y. H., Kemp, B. L., Walsh, G. and Mao, L. 1998. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58, 4082-4085. |
2 | Xu, X., Yamamoto, H., Liu, G., Ito, Y., Ngan, C. Y., Kondo, M., Nagano, H., Dono, K., Sekimoto, M. and Monden, M. 2008. CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells. Int. J. Mol. Med. 21, 145-152. |
3 | Xu, X., Yamamoto, H., Sakon, M., Yasui, M., Ngan, C. Y., Fukunaga, H., Morita, T., Ogawa, M., Nagano, H., Nakamori, S., Sekimoto, M., Matsuura, N. and Monden, M. 2003. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin. Cancer Res. 9, 1764-1772. |
4 | Zhou, B. B. and Elledge, S. J. 2000. The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439. DOI |
5 | Bertero, T., Gastaldi, C., Bourget-Ponzio, I., Mari, B., Meneguzzi, G., Barbry, P., Ponzio, G. and Rezzonico, R. 2013. Cdc25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ. 20, 800-811. DOI |
6 | Al-Rimawi, F., Rishmawi, S., Arigat, S. H., Khalid, M. F., Warad, I. and Salah, Z. 2016. Anticancer activity, antioxidant activity, and phenolic and flavonoids content of wild Tragopogon porrifolius plant extracts. Evid. Based Complement. Alternat. Med. 2016, 9612490. |
7 | Bartek, J. and Lukas, J. 2001. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490, 117-122. DOI |
8 | Bernardi, R., Liebermann, D. A. and Hoffman, B. 2000. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19, 2447-2454. DOI |
9 | Biomberg, I. and Hoffmann, I. 1999. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell Biol. 19, 6183-6194. DOI |
10 | Cai, Z., Chehab, N. H. and Pavletich, N. P. 2009. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol. Cell 35, 818-829. DOI |
11 | Donzelli, M. and Draetta, G. F. 2003. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677. DOI |
12 | Coulonval, K., Nockstaele, L., Paternot, S. and Roger, P. P. 2003. Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis. J. Biol. Chem. 278, 52052-52060. DOI |
13 | Devasagayam, T. P., Tilak, J. C., Boloor, K. K., Sane, K. S., Ghaskadbi, S. S. and Lele, R. D. 2004. Free radicals and antioxidants in human health: current status and future prospects. J. Assoc. Physicians India 52, 794-804. |
14 | Dickinson, B. C. and Chang, C. J. 2011. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat. Chem. Biol. 7, 504-511. DOI |
15 | Dorai, T. and Aggarwal, B. B. 2004. Role of chemopreventive agents in cancer therapy. Cancer Lett. 215, 129-140. DOI |
16 | Dulic, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J. and Reed, S. I. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023. DOI |
17 | Eymin, B., Claverie, P., Salon, C., Leduc, C., Col, E., Brambilla, E., Khochbin, S. and Gazzeri, S. 2006. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol. Cell Biol. 26, 4339-4350. DOI |
18 | Choi, I. P. 2013. Reactive oxygen species and cancer. Hanyang Med. Rev. 33, 118-122. DOI |
19 | Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M. and Beach, D. 1995. CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577. DOI |
20 | Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. and Lukas, J. 2001. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847. DOI |
21 | Halliwell, B. H. and Gutteridge, J. M. C. 1990. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186, 1-85. DOI |
22 | Gasparotto, D., Maestro, R., Piccinin, S., Vukosavljevic, T., Barzan, L., Sulfaro, S. and Boiocchi, M. 1997. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 57, 2366-2368. |
23 | GBD 2015 Risk Factors Collaborators. 2016. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1659-1724. DOI |
24 | Gonzalez-Burgos, E. and Gomez-Serranillos, M. P. 2012. Terpene compounds in nature: a review of their potential antioxidant activity. Curr. Med. Chem. 19, 5319-5341. DOI |
25 | Hanahan, D. and Weinberg, R. A. 2000. The hallmarks of cancer. Cell 100, 57-65. DOI |
26 | Hartwell, L. H. and Kastan, M. B. 1994. Cell cycle control and cancer. Science 266, 1821-1828. DOI |
27 | Kedare, S. B. and Singh, R. P. 2011. Genesis and development of DPPH method of antioxidant assay. J. Food Sci. Technol. 48, 412-422. DOI |
28 | Hoeijmakers, J. H. 2001. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374. DOI |
29 | Ito, Y., Yoshida, H., Uruno, T., Takamura, Y., Miya, A., Kuma, K. K. and Miyauchi, A. 2004. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 11, 295-300. DOI |
30 | Jin, P., Gu, Y. and Morgan, D. O. 1996. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J. Cell Biol. 134, 963-970. DOI |
31 | Mailand, N., Falck, J., Lukas, C., Syljuasen, R. G., Welcker, M., Bartek, J. and Lukas, J. 2000. Rapid destruction of Cdc 25A in response to DNA damage. Science 288, 1425-1429. DOI |
32 | Niedzwiecki, A., Roomi, M. W., Kalinovsky, T. and Rath, M. 2016. Anticancer efficacy of polyphenols and their combinations. Nutrients 8, E552. DOI |
33 | Malumbres, M. and Barbacid, M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166. DOI |
34 | Mraz, M., Malinova, K., Kotaskova, J., Pavlova, S., Tichy, B., Malcikova, J., Stano, K. K., Smardova, J., Brychtova, Y., Doubek, M., Trbusek, M., Mayer, J. and Pospisilova, S. 2009. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23, 1159-1163. DOI |
35 | Neergheen, V. S., Bahorun, T., Taylor, E. W., Jen, L. S. and Aruoma, O. I. 2010. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 278, 229-241. DOI |
36 | Nilsson, I. and Hoffmann, I. 2000. Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res. 4, 107-114. DOI |
37 | Singleton, V. L. and Rossi, J. A. 1965. Colorimetry of total phenolics with phosphomolybdic -phosphotungstic acid reagents. Am. J. Enol.Vitic. 16, 144-158. |
38 | O'Connor, P. M. 1997. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 29, 151-182. |
39 | Rix, M. 2013. LITSEA POPULIFOLIA. Curtis's Botanical Magazine 30, 193-200. DOI |
40 | Ryan, K. M., Phillips, A. C. and Vousden, K. H. 2001. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337. DOI |
41 | Vermeulen, K., Van Bockstaele, D. R. and Berneman, Z. N. 2003. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131-149. DOI |
42 | Vogelstein, B., Lane, D. and Levine, A. J. 2000. Surfing the p53 network. Nature 408, 307-310. DOI |